Update on Ambrose Healthcare shareholding
ValiRx Plc is providing an update on its shareholding in Ambrose Healthcare, a private pharmaceutical company, following Ambrose's acquisition of AM-Pharma for up to €161 million. ValiRx's subsidiary, ValiSeek, holds approximately 5.55% of Ambrose's issued share capital, acquired through an intellectual property license agreement for VAL401 and an earlier option agreement. ValiSeek is also entitled to clinical and commercial milestone payments of up to £16 million plus royalties. ValiRx views the acquisition positively, noting Ambrose's strengthened infrastructure and the potential for accelerated value inflection for ValiRx through its significant shareholding.
Select text to share a quote on X · sign in to keep highlights & notes in your VAL notes
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, notes the movement in the Company's share price on 20 October 2026 following the announcement by Ambrose Healthcare Ltd ("Ambrose"), a private UK specialist pharmaceutical company, regarding its acquisition of AM-Pharma for up to €161 million.
On 20 June 2025, ValiRx announced that its 54.14% owned subsidiary, ValiSeek Ltd ("ValiSeek"), a joint venture alongside Tangent Reprofiling, had entered into an intellectual property licence agreement with Ambrose in relation to VAL401. Under the agreement, ValiSeek received 576,000 ordinary shares in Ambrose and is entitled to clinical and commercial milestone payments of up to £16 million, together with royalties. In addition, ValiSeek received 75,000 ordinary shares in Ambrose in connection with the original option agreement. These shareholdings represents approximately 5.55% of Ambrose's issued share capital.
Mark Eccleston, CEO of ValiRx commented:
"As the third largest shareholder in Ambrose, we're delighted to see the acquisition of this additional clinical stage asset with established positive safety in almost 700 patients. The asset, which has had over $250M invested into sepsis-associated kidney injury including a Phase 3 trial that ultimately gave disappointing results, now has demonstrated dose-dependent effect on disease biomarkers in a Phase 1b study in adult HPP patients and has received Orphan Drug Designation for HPP from both the FDA and the EMA, with an agreed development plan built around a single pivotal study giving the programme a new lease of life with an established early clinical package. The acquisition also gives Ambrose an EU regulatory, quality and scientific infrastructure as a strong base for their pipeline which includes ValiSeek's VAL401 asset. Given the previous big pharma interest in the asset and accelerated clinical pathway via the orphan disease route we think this could be a fast tracked route to a significant value inflection for Ambrose and thus ValiRx through its shareholding."
The Directors of the Company take responsibility for this announcement.
| Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub | https://valirx.com/link/P7NqJr |
| ValiRx plc Dr Mark Eccleston, CEO | Tel: +44 115 784 0026 www.valirx.com Mark.Eccleston@valirx.com |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti | Tel: +44 (0) 20 7213 0880 |
| Shard Capital Partners LLP (Sole Broker) Damon Heath | Tel: +44 (0) 20 4530 6926 |
| V Formation (Public Relations) Jocelyn Braithwaite | +44 (0) 115 646 5491 www.vformation.co.uk jocelyn@vformation.co.uk |
Subscribe to our news alert service: https://valirx.com/s/f298d1
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.